This video illustrates what happens when a new science delivers on its promise? As terminal cancer patients begin to respond to an experimental drug, new hopes and challenges emerge. For the melanoma patients who signed on to try a drug known as PLX4032, the clinical trial was a last resort. Their bodies were riddled with tumors, leaving them almost certainly just months to live. But a few weeks after taking their first dose, nearly all of them began to recover. The second in a series.